Kayla King is an associate in the corporate department of Ropes & Gray. She advises emerging companies on startup and formation matters, and supports both early-stage companies and venture capital funds in equity financing transactions. Kayla also represents private and public companies in capital markets and other strategic transactions, and regularly collaborates with companies on securities law compliance and corporate governance matters.
During law school, Kayla completed legal externships at a global software company and a fintech-focused international nonprofit organization, and worked in the BU/MIT Student Innovations Law Clinic and the Compliance Policy Clinic. In addition, Kayla served as a Lawyering Fellow, president of the Business Law Society, president of the Real Estate Association, vice president of the Women of Color Collaborative, and vice president of alumni relations of the Asian Pacific American Law Students Association.
Prior to law school, Kayla worked at a full-service marketing and fundraising agency in Los Angeles, California.
Experience
Representative Emerging Company & Venture Capital Matters
- Represented Bain Capital Life Sciences on the creation of a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launched with five immunology assets in-licensed from Bristol Myers Squibb and a $300 million financing commitment that was led by Bain Capital.
- Represented Creyon Bio in a global licensing and multi-target research collaboration with Eli Lilly and in ongoing corporate and financing matters.
- Advised Dash Bio, a biotechnology company revolutionizing clinical bioanalysis, in its formation and in raising $17.5 million in initial funding, and in ongoing general corporate matters.
- Advised the Collaborative Fund on an investment in Smash Kitchen, a business venture by actor and producer Glen Powell.
- Represented Partners Group in acquiring a significant minority stake in restor3d, a leader in technology-driven personalized orthopedic solutions, marking the company's first institutional investment.
- Represented Pfizer in a novel strategic partnership with Flagship Pioneering, valued at up to $7 billion, to create a new pipeline of innovative medicines; represented Pfizer Ventures in various transactions.
- Represented Novo Nordisk in an equity investment in Metaphore Biotechnologies, a biotechnology company designing drugs by combining machine learning and molecular mimicry.
- Represented The RockCreek Group in co-leading Forge Nano’s $40 million Series D financing, a technology company pioneering domestic battery and semiconductor innovations.
Representative Capital Markets & Corporate Governance Matters
- Represented the lead underwriters in Sionna Therapeutics’ $219 million initial public offering.
- Represented Surgery Partners in connection with its Rule 144A/Reg S $800 million high yield senior notes offering and the redemption of two series of its outstanding senior notes.
- Represented the initial purchasers in connection with Apollo Debt Solutions BDC’s inaugural Rule 144A/Reg S $650 million senior notes offering.
- Ongoing representation of public company clients in connection with securities law and corporate governance matters.